EU Institutions Scale Up Shortages Action Amid Growing COVID Threat
But Pharma Firms Must Ensure Continuity Of Drug Supplies
The EU institutions are intensifying their efforts to mitigate the impact of COVID-19 on medicine provision, with a new group set to coordinate Europe-wide actions.
You may also be interested in...
The deputy head of the European Medicines Agency has outlined the steps the agency is taking to assess and address the possibility of drug shortages in Europe caused by the coronavirus outbreak, as the number of cases worldwide tops the 98,000 mark.
The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.
The pharmaceutical industry has given a muted welcome to proposals for building up the EU's resilience to medicine shortages, saying many of the ideas will not tackle the root causes of supply problems and could even serve to undermine innovation.